[PDF] snmjournals.orgFree from Publisher

177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy

RP Baum, HR Kulkarni, C Schuchardt… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The objective of this study was to analyze the safety and efficacy of the 177Lu-labeled
DOTAGA-based prostate-specific membrane antigen (PSMA) ligand 177Lu-DOTAGA-(Iy) fk …
Save Cite Cited by 481 Related articles All 10 versions
[PDF] snmjournals.org

Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy

RP Baum, HR Kulkarni, C Schuchardt… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The objective of this study was to analyze the safety and efficacy of the 177 Lu-labeled
DOTAGA-based prostate-specific membrane antigen (PSMA) ligand 177 Lu-DOTAGA-(Iy) fk …
Save Cite Cited by 98 Related articles All 2 versions
[PDF] ajronline.orgFull View

Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

MP Yadav, S Ballal, RK Sahoo… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
Save Cite Cited by 166 Related articles All 3 versions
[PDF] academia.edu

Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer

MM Heck, R Tauber, S Schwaiger, M Retz… - European urology, 2019 - Elsevier
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is
increasingly being used in metastatic castration-resistant prostate cancer (mCRPC). The …
Save Cite Cited by 250 Related articles All 4 versions

Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration …

MM Heck, M Retz, C D'Alessandria… - The Journal of …, 2016 - auajournals.org
Purpose: We report our initial clinical experience with β-emitting 177Lu-PSMA-I&T (177Lu
labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic …
Save Cite Cited by 196 Related articles All 9 versions
[PDF] snmjournals.orgFree from Publisher

Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer …

C Schuchardt, J Zhang, HR Kulkarni… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …
Save Cite Cited by 73 Related articles All 7 versions
[PDF] snmjournals.orgFree from Publisher

177Lu-PSMA radioligand therapy for prostate cancer

WP Fendler, K Rahbar, K Herrmann… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using
inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration …
Save Cite Cited by 205 Related articles All 12 versions
[HTML] springer.com

[HTML][HTML] Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate …

R Manafi-Farid, S Harsini, B Saidi… - European Journal of …, 2021 - Springer
Background Prostate cancer (PC) is one of the most common cancers in men. Although the
overall prognosis is favorable, the management of metastatic castration-resistant prostate …
Save Cite Cited by 29 Related articles All 11 versions

Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer

K Rahbar, A Bode, M Weckesser… - Clinical nuclear …, 2016 - journals.lww.com
Background Despite progress in treatment of metastatic castration-resistant prostate cancer
(mCRPC), new approaches are urgently needed. Recently theranostic concepts using …
Save Cite Cited by 200 Related articles All 3 versions
[HTML] springer.com

[HTML][HTML] 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

F Khreish, Z Ghazal, RJ Marlowe, F Rosar… - European Journal of …, 2022 - Springer
Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …
Save Cite Cited by 47 Related articles All 11 versions